NeuroLight

NeuroLight operates at the intersection of neurotechnology, medical devices, health care, and artificial intelligence. Its stated approach differs from software-only wellness products by using light and sound as physical stimuli to influence brain activity. The company describes a brain-state transfer concept: recording neural activity associated with a desired state and seeking to reproduce that activity. The company is categorized as a medical-device and health-care business, placing it in a field that can include neurostimulation developers and digital sleep-health companies. NeuroLight’s differentiator is therefore best understood as its combined light-and-sound modality and brain-state framing, rather than a proven advantage in outcomes or scale.

Founded in November 2017, NeuroLight has pursued a long-running development effort centered on light- and sound-based neuromodulation. During 2025, the company was described as hiring across finance, strategy, clinical leadership, and non-dilutive funding roles. The company’s recorded employee range remains one to ten, indicating a small organization rather than evidence of substantial headcount expansion. No product launches, later funding rounds, valuation, or quantified employee-growth data are documented here. The main observable inflection points are the 2024 research grant and the reported 2025 recruiting activity. Whether these steps translated into clinical validation, a market-ready device, or commercial growth remains unclear. The trajectory is therefore consistent with continued early-stage development, but public indicators are insufficient to establish the pace or success of commercialization.